Open AccessCharacterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma
Author(s) -
Norma E. Farrow,
Eda K. Holl,
Jeanne Jung,
Junheng Gao,
Sin Ho Jung,
Rami N. AlRohil,
M. Angélica Selim,
Paul J. Mosca,
David W. Ollila,
Scott Antonia,
Douglas S. Tyler,
Smita K. Nair,
Georgia M. Beasley
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-09277-w
Subject(s) - medicine , oncology , proportional hazards model , melanoma , sentinel lymph node , retrospective cohort study , adjuvant therapy , surgical oncology , cohort , lymph node , cancer , breast cancer , cancer research
Although sentinel lymph node (SLN) biopsy is a standard procedure used to identify patients at risk for melanoma recurrence, it fails to risk-stratify certain patients accurately. Because processes in SLNs regulate anti-tumor immune responses, the authors hypothesized that SLN gene expression may be used for risk stratification.